Monitoring strategies in adults eligible for pharmacological lipid-lowering therapy

Q: What is the clinical evidence from this study?

Study design: Systematic Review. Population: Cardiovascular disease prevention. Intervention: Laboratory monitoring strategies vs. Alternative monitoring strategy or no routine testing.

Kamyar Shokraee; Brenda W. C. Bongaerts; Petek Eylul Taneri; Camila Micaela Escobar Liquitay; Siavosh Olfati; Ana-Mihaela Zorger; Nicole Skoetz; Juan Víctor Ariel Franco

doi:10.1002/14651858.cd016386

September 18, 2026Cochrane libraryOpen Access

Monitoring strategies in adults eligible for pharmacological lipid-lowering therapy

View Full Paper

Ask AI

Bookmark

Share

Key result

Protocol outlines Cochrane review evaluating laboratory monitoring strategies during lipid-lowering therapy.

Why the study?

The effects of different laboratory monitoring strategies for efficacy and safety in adults receiving pharmacological lipid-lowering therapy for cardiovascular prevention are unclear.

Do different laboratory monitoring strategies improve clinical outcomes and safety in adults receiving pharmacological lipid-lowering therapy?

Key Points

To assess the effects of different laboratory monitoring strategies for treatment efficacy and safety in adults eligible for or receiving pharmacological lipid-lowering therapy for primary or secondary cardiovascular disease prevention.
Protocol for a Cochrane systematic review evaluating different laboratory monitoring panels and testing schedules (frequency and timing).
Analysis plans to assess short-term (≤ 12 months), medium-term (> 12 to 36 months), and long-term (> 36 months) follow-up durations.
Outcomes prioritized for clinical decision-making include all-cause mortality, atherosclerotic cardiovascular disease death, 3-point major adverse cardiovascular events (MACE), lipid levels, and adverse events.
No clinical trial findings are reported because this publication is a protocol outlining the rationale and methods for an upcoming systematic review.
Planned efficacy analyses will assess changes in lipid levels, including low-density lipoprotein cholesterol (LDL-C), total cholesterol, and triglycerides, alongside cardiovascular outcomes.
Planned safety analyses will evaluate adverse events including hepatotoxicity (elevated ALT/AST transaminases), muscle symptoms, and myopathy or rhabdomyolysis related to creatine kinase elevation.

Study Design

Type

Systematic Review

Structured PICO

Do different laboratory monitoring strategies improve clinical outcomes and safety in adults receiving pharmacological lipid-lowering therapy?

P

Population

This is a protocol for a Cochrane systematic review to evaluate laboratory monitoring strategies in adults eligible for or receiving lipid-lowering therapy, with no results reported yet.

I

Intervention

Different laboratory monitoring strategies (variations in baseline testing panels, follow-up testing panels, or frequency/timing of repeat testing).

C

Comparator

Alternative testing panel (reduced/minimal testing panel) or no routine testing (testing only if clinically indicated).

O

Outcome

All-cause mortality, ASCVD death, 3-point MACE, stroke or TIA, coronary heart disease, adverse events, lipid levels.

This protocol defines a systematic methodology to evaluate the effects of different laboratory monitoring strategies in patients prescribed lipid-lowering therapies.

Implication

Protocol reports no results; leaves optimal lab monitoring strategies for lipid-lowering therapy open pending planned Cochrane review.

Abstract

OBJECTIVES: This is a protocol for a Cochrane review (intervention). The objectives are as follows: To assess the effects of different laboratory monitoring strategies for treatment efficacy (lipid levels) and treatment safety (hepatic, muscular, and renal parameters) in adults eligible for or receiving pharmacological lipid-lowering therapy for primary and/or secondary prevention of cardiovascular disease, including whether such monitoring is performed and the frequency or timing with which it is repeated.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Shokraee et al. (2026) conducted a systematic review in Cardiovascular disease prevention. Laboratory monitoring strategies vs. Alternative monitoring strategy or no routine testing was evaluated. This paper describes a protocol for a Cochrane systematic review assessing laboratory monitoring strategies in adults receiving lipid-lowering therapy, and therefore contains no clinical results.

synapsesocial.com/papers/6ad0fd4715427f6a8404062f https://doi.org/10.1002/14651858.cd016386

View Full Paper

Ask AI

Bookmark

Share

Monitoring strategies in adults eligible for pharmacological lipid-lowering therapy

Key Points

Study Design

Structured PICO

Implication

Abstract

Discussion

Cite This Study

Monitoring strategies in adults eligible for pharmacological lipid-lowering therapy

Key Points

Study Design

Structured PICO

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Cochrane library

Keep reading

More related papers

More from Cochrane library